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MaBACKGROUND The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the
sulfate DHEA-S, is the most abundant steroid hormone in human blood. Its levels decline dramatically with age. Despite
the great amount of literature on vascular and metabolic actions of DHEA/-S, evidence for an association between
DHEA/-S levels and cardiovascular events is contradictory.
OBJECTIVES This study tested the hypothesis that serum DHEA and DHEA-S are predictors of major coronary heart
disease (CHD) and/or cerebrovascular disease (CBD) events in a large cohort of elderly men.
METHODS We used gas and liquid chromatography-mass spectrometry to analyze baseline levels of DHEA and DHEA-S
in the prospective population-based Osteoporotic Fractures in Men study in Sweden (2,416 men, ages 69 to 81 years).
Complete cardiovascular clinical outcomes were available from national Swedish registers.
RESULTS During the 5-year follow-up, 302 participants experienced a CHD event, and 225 had a CBD event. Both DHEA
and DHEA-S levels were inversely associated with the age-adjusted risk of a CHD event; the hazard ratios and 95%
conﬁdence intervals per SD increase were 0.82 (0.73 to 0.93) and 0.86 (0.77 to 0.97), respectively. In contrast, DHEA/-S
showed no statistically signiﬁcant association with the risk of CBD events. The association between DHEA and CHD risk
remained signiﬁcant after adjustment for traditional cardiovascular risk factors, serum total testosterone and estradiol,
C-reactive protein, and renal function, and remained unchanged after exclusion of the ﬁrst 2.6 years of follow-up to
reduce reverse causality.
CONCLUSIONS Low serum levels of DHEA and its sulfate predict an increased risk of CHD, but not CBD, events
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ABBR EV I A T I ON S
AND ACRONYMS
ApoA1 = apolipoprotein A1
ApoB = apolipoprotein B
BMI = body mass index
CBD = cerebrovascular disease
CHD = coronary heart disease
CV = coefﬁcient of variation
CVD = cardiovascular disease
DHEA =
dehydroepiandrosterone
DHEA-S =
dehydroepiandrosterone
sulfate
eGFR = estimated glomerular
ﬁltration rate
hsCRP = high-sensitivity
C-reactive protein
ICD = International
Classiﬁcation of Diseases
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1802consequences for health are unclear (5).
DHEA has been hypothesized to be important
for body composition, insulin sensitivity, and
endothelial function (1,4,6), and DHEA may
reduce vascular inﬂammation and remodel-
ing, platelet aggregation, oxidative stress,
and atherosclerosis, which suggests that
DHEA may confer vascular protection (1–3,6–
9). Consequently, it has been speculated that
relative DHEA/-S deﬁciency with increasing
age may contribute to age-related cardio-
metabolic disease (4). However, although
there is a relatively large body of published
data on the vascular and metabolic actions of
DHEA in experimental models, the relevance
of these results for human physiology and
pathophysiology is uncertain (4).SEE PAGE 1811Several studies that addressed the associ-
ation between DHEA/-S levels and cardio-vascular disease (CVD) outcomes showed inconsistent
ﬁndings (6,10–15). In prospective studies, our group
and others previously reported an increased risk of
both all-cause and CVD mortality among elderly men
with the lowest DHEA/-S levels (16–18). However, the
data regarding DHEA/-S and CVD mortality in men
also conﬂict (19,20) and may be confounded by
DHEA/-S levels that are suppressed in severe illness
(21,22). One prospective study reported an association
between low DHEA/-S and combined fatal and
nonfatal coronary heart disease (CHD) events in men
only when self-report of treated CHD and CHD medi-
cation were included as events in the analysis (23).
Thus, there is a need for large population-based
studies to address the potential association between
DHEA/-S and CVD outcomes.
The aim of the present study was to test the hy-
pothesis that serum DHEA and/or DHEA-S levels are
predictors of major CHD and/or cerebrovascular dis-
ease (CBD) events in a large population-based cohort of
elderly men. We used state-of-the-art methodology to
assay baseline DHEA and DHEA-S serum levels, and
had a complete 5-year follow-up for CHD (including
hospitalization for acute myocardial infarction, un-
stable angina, or revascularization, or death fromCHD)
and CBD (including hospitalization for stroke or tran-
sient ischemic attack, or death from stroke) endpoints.
METHODS
STUDY POPULATION. The multicenter MrOS (Osteo-
porotic Fractures in Men Study) includes older men in
Sweden, Hong Kong, and the United States. Swedishstudy participants (age 69 to 81 years) were randomly
selected from national population registers (24).
Eligibility required the ability to walk without
walking aids, ability to provide self-reported data,
and to understand and sign an informed consent; 45%
of those contacted participated in the MrOS Study
in Sweden (n ¼ 3,014), which included cohorts in
3 cities: Malmö (n ¼ 1,005), Göteborg (n ¼ 1,010),
and Uppsala (n ¼ 999). The ethics committees at
Göteborg, Lund, and Uppsala Universities approved
the study.
We investigated the associations between serum
DHEA and DHEA-S with CHD and/or CBD events in the
Swedish MrOS cohort. Serum samples were drawn in
themorning (before 10 AM; 69%of the cohort) or around
noon (between 10 AM and 3 PM, average 1 PM; 31%).
A sufﬁcient amount of serum for assessment of
DHEA by gas chromatography-mass spectroscopy
was available for 2,639 men (99% of the participants
in the Göteborg cohort, 96% in the Malmö cohort,
and 68% in the Uppsala cohort). Of these, 223 partici-
pants were excluded for the following reasons: treat-
ment with testosterone, 5alpha-reductase inhibitors,
gonadotrophin-releasing hormone agonists, or anti-
androgens, or the participants had a history of surgical
castration. This left 2,416men for the present analyses.
ASSESSMENT OF COVARIATES. We used a stan-
dardized questionnaire (25) to gather information
about smoking habits and self-reported medical
diagnoses (including hypertension, diabetes, and
myocardial infarction). Diabetes was deﬁned as a self-
reported medical diagnosis of diabetes. Hypertension
was deﬁned as a self-reported medical diagnosis with
either self-reported antihypertensive treatment or
a supine systolic blood pressure of $140 mm Hg
(measured after a 10-min rest). Standard equipment
was used to measure height and weight; body mass
index (BMI) was calculated as kilograms (weight)/
meters squared (height).
Apolipoprotein B (ApoB) and apolipoprotein A1
(ApoA1) were determined by immunoprecipitation
enhanced by polyethylene glycol at 340 nm (Thermo
Fisher Scientiﬁc, Vantaa, Finland). High-sensitivity
C-reactive protein (hsCRP) was measured by an
ultrasensitive method (Orion Diagnostica, Espoo,
Finland). Both analyses were performed on a Konelab
20 autoanalyzer (Thermo Fisher Scientiﬁc). Inter-
assay coefﬁcients of variation (CVs) for the Konelab
analyses were <5%.
For assessment of the estimated glomerular
ﬁltration rate (eGFR), cystatin C was analyzed with
polyclonal antibodies against human cystatin C
and measured by immunoturbidimetry (Cystatin C
Immunoparticles; Dako Denmark A/S, Glostrup,
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following formula: GFR ¼ 79.901  (cystatin C) –
1.4389. This proxy for the GFR has good precision and
linearity, and a strong correlation with iohexol
clearance (R2 ¼ 0.956) (26).
SERUM SEX STEROIDS. All samples were frozen at
–80C and shipped on dry ice to 1 laboratory (Labo-
ratory of Molecular Endocrinology, Laval University
Hospital Research Center, Québec City, Québec,
Canada). A validated gas chromatography-mass
spectroscopy system (27–29) was used to analyze
DHEA (limit of detection, 0.20 ng/ml; intra-assay CV,
2.0%; interassay CV, 1.9%), testosterone (limit of
detection, 0.05 ng/ml; intra-assay CV, 2.9%; inter-
assay CV, 3.4%), and estradiol (limit of detection,
2.00 pg/ml; intra-assay CV, 1.5%; interassay CV, 2.7%)
using a 50% phenyl-methyl polysiloxane (DB-17HT)
capillary column (30-m  0.25-mm internal diameter;
0.15-mm ﬁlm thickness) with helium as the carrier gas.
The analytes and the internal standard were detected
using a HP5973 quadrupole mass spectrometer
equipped with a chemical ionization source. DHEA-S
(limit of detection, 0.075 mg/ml; intra-assay CV,
5.2%; interassay CV, 6.3%) was analyzed by a vali-
dated liquid chromatography-tandem mass spectros-
copy method using turbo ion spray, as previously
described (27). To measure the serum sex hormone–
binding globulin, we used an immunoradiometric
assay (Orion Diagnostics, Espoo, Finland; limit of
detection, 1.3 nmol/l; intra-assay CV, 3%; interassay
CV, 7%).
STUDY OUTCOMES. Follow-up time was the period
between the baseline visit (in 2001 to 2004) and the
date of death, ﬁrst CHD/CBD event, or last data
collection (December 31, 2008). Cause-of-death data
were collected from the Swedish Causes of Death
Register, which is held by the National Board of
Health and Welfare in Sweden, in which all deaths in
Sweden are registered with International Classiﬁca-
tion of Diseases (ICD) codes based on information
from death certiﬁcates. Data were collected from this
register from study start until December 31, 2005 and
from evaluation of copies of death certiﬁcates for
deaths occurring after this date up to 2008. Based on
the information from the register and/or death cer-
tiﬁcate, the underlying cause of death was deter-
mined and classiﬁed for each participant. CHD death
was deﬁned by ICD-10 codes I20 to I25 and stroke
death by codes I60 to I64. Data on hospitalization for
ﬁrst acute myocardial infarction (ICD-10 codes I21 to
I23), unstable angina (ICD-10 codes I20.0 and I24),
revascularization procedure (surgery code FN), stroke
(ICD-10 codes I60 to I64), or transient ischemic attack(ICD-10 code G45) were collected from the Swedish
Hospital Discharge Register between the baseline
date and December 31, 2008. The combination of data
from the Swedish Causes of Death Register and the
Swedish Hospital Discharge Register was shown to be
an efﬁcient, validated alternative to hospital dis-
charge notes and death certiﬁcates for both CHD and
stroke (30). CHD events were deﬁned as a composite
endpoint of hospitalization for acute myocardial
infarction, unstable angina or revascularization, or
death from CHD. CBD events included hospitaliza-
tion for stroke or transient ischemic attack, or death
from stroke. Death due to causes other than CHD (for
the analyses of CHD events) or stroke (for the anal-
yses of CBD events) resulted in censoring in the
analyses.
STATISTICAL ANALYSIS. The associations between
serum log-transformed DHEA and DHEA-S, as well as
serum DHEA/-S and total testosterone, estradiol, and
sex hormone–binding globulin (log-transformed)
were tested by Pearson correlation. Covariates of
serum DHEA/-S were studied in a multiple regression
model with log-transformed DHEA/-S as the depen-
dent variable; age, morning sample (yes/no), MrOS
site (dummy-coded), BMI (log-transformed), the
ApoB/A1 ratio, serum hsCRP (log-transformed), eGFR,
current smoking status, diabetes, and hypertension
were used as the independent variables.
We used Cox proportional hazards regression to
analyze the associations between serum DHEA
and DHEA-S and CVD outcomes (ﬁrst CHD or CBD
event). The proportional hazard function was
tested (using a method developed by Therneau and
Grambsch [31]) and graphically assessed on the basis
of Schoenfeld residuals for both CHD and CBD
models. No systematic deviations from proportion-
ality were detected. We show the effect estimate for
a 1-SD increase (z score) of log-transformed DHEA/-S
levels. All estimates were adjusted for age and
morning sample (yes/no). Furthermore, all Cox anal-
yses were adjusted for MrOS site (dummy coded),
and there were similar associations between DHEA
(per SD) and CHD events across the 3 MrOS sites
(data not shown). Further adjustments were made
for BMI (log-transformed), the ApoB/A1 ratio, serum
hsCRP (log-transformed), serum total estradiol and
testosterone, serum sex hormone–binding globulin
(log-transformed), and eGFR as continuous vari-
ables, as well as 3 dichotomous variables (current
smoking status, diabetes, and hypertension). We
also examined the associations between DHEA/-S
and outcomes across the components of the CHD
composite endpoint.
TABLE 2 Univariate Covariates of DHEA and DHEA-S Levels
DHEA* DHEA-S*
R p Value R p Value
Morning sample† 0.24 <0.001 –0.01 0.51
Age –0.22 <0.001 –0.19 <0.001
BMI* –0.10 <0.001 –0.05 0.011
ApoB/A1 –0.04 0.047 –0.02 0.25
hsCRP* –0.11 <0.001 –0.07 <0.001
Current smoking† 0.04 0.026 0.05 0.008
Diabetes† –0.06 0.004 –0.07 <0.001
Hypertension† –0.05 0.011 –0.03 0.10
eGFR 0.15 <0.001 0.09 <0.001
*Log10-transformed values of DHEA, DHEA-S, BMI, and hsCRP were used.
†Yes ¼ 1, no ¼ 0 for dichotomous variables.
Abbreviations as in Table 1.
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trated the association between tertiles of DHEA and
CHD, as well as CBD events. The log-rank test
assessed statistical signiﬁcance. DHEA/-S was entered
as a quadratic term in the Cox regression analyses to
test for possible nonlinearity in the association be-
tween DHEA and CHD outcomes. In addition, in the
Cox regression analysis, we used a restricted cubic
spline approach for a ﬂexible nonlinear assessment of
the hazard ratio (HR) in relation to DHEA (32). The
positions and the number of knots were selected
using the Akaike Information Criterion (33). Five
knots positioned at the 10th, 25th, 50th, 75th, and
90th percentiles of log-transformed serum DHEA
concentration provided a small Akaike Information
Criterion and captured the average curve shape over a
systematical assessment of different alternatives. In
the analysis that used a spline approach, age and
MrOS site were entered as covariates.
We performed the restricted cubic spline analysis
using SAS (version 9.2, SAS Institute, Cary, North
Carolina), and the other statistical analyses were
performed using SPSS for Windows (version 19.0,
SPSS, Chicago, Illinois).
RESULTS
At baseline, the mean age of the cohort (n ¼ 2,614)
was 75.4 years (Table 1). Serum levels of DHEA and
DHEA-S in the cohort were highly collinear (r ¼ 0.73;
p < 0.001), but their covariates differed slightly
(Tables 2 and 3). The covariates of DHEA and DHEA-S
levels in a multiple regression model (Table 3) wereTABLE 1 Characteristics of the Study Participants (N ¼ 2,416)
Age, yrs 75.4  3.2
BMI, kg/m2* 26.1  1.1
ApoB/A1 ratio 0.72  0.20
hsCRP, mg/l* 2.63  2.36
Current smoking 8.4
Diabetes 9.4
Hypertension 34.3
eGFR, ml/min/1.73 m2 71.9  20.5
DHEA, ng/ml 1.79  1.20
DHEA-S, mg/ml 0.71  0.46
Testosterone, ng/ml 4.53  1.73
Estradiol, pg/ml 21.1  7.5
SHBG, nmol/l 44  22
Values are mean  SD or %. Diabetes was deﬁned as a self-reported medical
diagnosis of diabetes. Hypertension was deﬁned as a self-reported medical diag-
nosis with either self-reported antihypertensive treatment or a supine systolic
blood pressure of $140 mm Hg. *Geometric mean  SD.
ApoA1 ¼ apolipoprotein A1; ApoB ¼ apolipoprotein B; BMI ¼ body mass index;
hsCRP ¼ high-sensitivity C-reactive protein; DHEA ¼ dehydroepiandrosterone;
DHEA-S ¼ DHEA sulfate; eGFR ¼ estimated glomerular ﬁltration rate; SHBG ¼ sex
hormone–binding globulin.age, BMI, hsCRP, and diabetes. Together with these
factors, DHEA, but not DHEA-S, levels were also
highly inﬂuenced by the time of blood sampling and
renal function.
During follow-up, a total of 302 participants expe-
rienced a CHD event (rate of 2.5 per 100 person-years
at risk), and 225 participants had a CBD event (1.9 per
100 person-years at risk). The median follow-up time
(to death, ﬁrst event, or last data collection) was
5.2 years (12.070 person-years) for CHD events and
5.2 years (12.137 person-years) for CBD events. Except
for 3 participants who moved abroad, there was no
loss of follow-up.
In prospective analyses, DHEA and DHEA-S levels
were both inversely associated with the age-adjusted
risk of CHD events when analyzed as continuous
variables (Table 4, Model 1). In contrast, there was no
statistically signiﬁcant association between DHEA
or DHEA-S and CBD events in the corresponding
analyses (Table 4). After adjustment for traditional
cardiovascular risk factors (age, BMI, smoking, dia-
betes, hypertension, and the ApoB/A1 ratio; Model 2),
the associations between DHEA/-S and CHD risk
remained signiﬁcant (Table 4). Spline and quadratic
models did not support a nonlinear association
between DHEA level and CHD risk (Figure 1, and data
not shown).
Because DHEA/-S may modulate immune re-
sponses (7), we addressed inﬂammation as a potential
mediator between a lower DHEA/-S level and
increased CHD risk. Adjustment of the association for
hsCRP level did not materially change the association
between DHEA/-S and CHD risk (Table 4).
Both DHEA and DHEA-S levels were directly asso-
ciated with renal function as assessed by eGFR
(Table 2). Therefore, we adjusted the association be-
tween DHEA/-S and CHD risk for eGFR and found that
TABLE 3 Multivariate Correlations of DHEA and DHEA-S Levels
DHEA* DHEA-S*
Standardized
Beta Coefﬁcient p Value
Standardized
Beta Coefﬁcient p Value
Morning sample† 0.22 <0.001 0.01 0.68
Age –0.19 <0.001 –0.20 <0.001
BMI* –0.09 <0.001 –0.05 0.013
ApoB/A1 0.04 0.072 –0.02 0.43
hsCRP* –0.07 <0.001 –0.06 0.009
Current smoking† 0.04 0.046 0.04 0.064
Diabetes† –0.05 0.010 –0.06 0.002
Hypertension† –0.01 0.60 –0.00 0.85
eGFR 0.08 <0.001 0.02 0.31
*Log10-transformed values of DHEA, DHEA-S, BMI, and hsCRP were used. †Yes ¼ 1, no ¼ 0 for
dichotomous variables.
Abbreviations as in Table 1.
TABLE 4 Adjusted Hazard Ratios of DHEA and DHEA-S as Continuous Variables
for CHD and CBD Events
Number of CHD Events/
Number of Subjects HR (95% CI)
DHEA-S
HR (95% CI)
CHD events
Per SD increase; Model 1 302/2,416 0.82 (0.73–0.93)
p ¼ 0.001
0.86 (0.77–0.97)
p ¼ 0.011
Per SD increase; Model 2 290/2,341 0.83 (0.73–0.94)
p ¼ 0.002
0.87 (0.78–0.98)
p ¼ 0.022
Per SD increase;
Model 2 þ hsCRP
290/2,341 0.84 (0.74–0.95)
p ¼ 0.005
0.88 (0.78–0.99)
p ¼ 0.030
Per SD increase;
Model 2 þ eGFR
289/2,324 0.85 (0.75–0.96)
p ¼ 0.007
0.88 (0.78–0.99)
p ¼ 0.031
Per SD increase;
Model 2 þ estradiol
and testosterone
290/2,341 0.83 (0.73–0.94)
p ¼ 0.003
0.87 (0.78–0.98)
p ¼ 0.020
Per SD increase;
Model 2 þ SHBG
290/2,341 0.83 (0.74–0.94)
p ¼ 0.003
0.87 (0.77–0.97)
p ¼ 0.015
CBD events
Per SD increase; Model 1 225/2,416 0.91 (0.79–1.04)
p ¼ 0.17
0.90 (0.79–1.02)
p ¼ 0.11
Per SD increase; Model 2 222/2,341 0.90 (0.79–1.04)
p ¼ 0.16
0.90 (0.79–1.02)
p ¼ 0.10
Model 1: adjustment for age, MrOS site, morning sample. Model 2: Model 1 þ current smoking, BMI, diabetes,
hypertension, ApoB/A1. Log10-transformed values of DHEA, DHEA-S, BMI, and hsCRP were used. The propor-
tional hazards assumption was met for both CHD and CBD models.
CHD ¼ coronary heart disease; CBD ¼ cerebrovascular disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio;
other abbreviations as in Table 1.
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change (Table 4).
DHEA/-S is a precursor hormone for testosterone
and estradiol (4). DHEA showed an association with
serum testosterone (r ¼ 0.21; p < 0.001) and estradiol
(r ¼ 0.14; p < 0.001) that was slightly stronger than
the association between DHEA-S and testosterone
(r ¼ 0.05; p ¼ 0.010) and estradiol (r ¼ 0.06;
p ¼ 0.005), respectively. After the adjustment of the
association between low DHEA/-S and CHD risk for
serum total testosterone and estradiol, the associa-
tions remained unchanged (Table 4).
We also examined the association between DHEA/-S
and the sex hormone–binding globulin, which has
an important role in sex hormone biology (34). Sex
hormone–binding globulin levels were signiﬁcantly
associated with DHEA-S (r ¼ –0.09; p < 0.001), but
these levels were not associated with DHEA (r ¼ 0.03;
p ¼ 0.095). Adjustment for the sex hormone–binding
globulin level did not change the association between
DHEA/-S and CHD events (Table 4).
In a subanalysis, we examined the associations
between DHEA/-S and outcomes across the compo-
nents of the CHD composite endpoint (Online
Table S1). We found that the point estimates for the
DHEA/-S association with CHD death, hospitalization
for myocardial infarction, hospitalization for unstable
angina, and hospitalization for revascularization were
all in the same direction; the strongest point esti-
mates were for CHD death and hospitalization for
unstable angina, and the weakest point estimates
were for revascularization procedures.
To illustrate the association between DHEA status
and CVD risk, we plotted unadjusted Kaplan-Meier
curves of CHD and CBD event-free survival stratiﬁed
by DHEA tertiles. These plots illustrated that men
with relatively lower DHEA levels had a statistically
signiﬁcantly increased risk of a CHD event (Figure 2A),
but did not have an increased risk of a CBD event
(Figure 2B).
DHEA levels are suppressed in severe illness
(21,22). Therefore, general health status is a potential
confounder of observed associations. To study the
role of subclinical diseases, we performed an analysis
that excluded men with a short follow-up time, which
is indicative of poor health at the baseline examina-
tion. After exclusion of men with a follow-up of
2.6 years or less (one-half of the median follow-up
time), the age-adjusted association between low
DHEA levels and CHD risk was not attenuated
(Table 5). Similarly, the association between DHEA
and CHD risk remained following the exclusion of
men with reduced renal function (eGFR #45 ml/min/
1.73 m2) and men without morning samples.Furthermore, the association between DHEA and CHD
risk remained after exclusion of men with a baseline
history of myocardial infarction.
DISCUSSION
In the present large, population-based cohort study of
elderly men followed for 5 years, we found that
baseline serum levels of DHEA and DHEA-S predicted
future CHD events (Central Illustration). In contrast,
DHEA/-S showed no statistically signiﬁcant
3.0
2.0
1.0
0.0
-1.0
-1.0
(0.1 ng/ml) (1.0 ng/ml) (10 ng/ml)
0
Serum LogDHEA
 L
og
HR
1.0
-2.0
FIGURE 1 Smoothed Plots of Log-Transformed HR for
CHD Events According to Serum DHEA Concentration
DHEA levels were log10-transformed; corresponding serum
levels are shown in italics. HRs (red solid line) and 95% conﬁ-
dence intervals (slate dotted lines) were estimated by restricted
cubic spline Cox regression analysis, using the median serum
DHEA concentration (1.5 ng/ml) as the reference value. Five
knots were positioned at the 10th, 25th, 50th, 75th, and 90th
percentiles of serum logDHEA concentration. The horizontal
dashed line corresponds to the reference (1.5 ng/ml) HR of 1.0.
The model is adjusted for age and MrOS (Osteoporotic Fractures
in Men) study site. p (effect) ¼ 0.001; p (nonlinearity) ¼ 0.1.
CHD ¼ coronary heart disease; DHEA ¼ dehydroepiandrosterone;
HR ¼ hazard ratio.
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tion between DHEA and CHD risk remained signiﬁ-
cant after adjustment for traditional cardiovascular
risk factors, serum testosterone and estradiol levels,
hsCRP, and renal function. Furthermore, the associ-
ation between DHEA and CHD risk was not materially
changed in the analyses that excluded the ﬁrst 2.6
years of follow-up.
Previous epidemiological evidence of an associa-
tion between DHEA/-S levels and CVD outcomes in
men are contradictory (10–20,23,35). A prospective,
nested case–control study reported lower DHEA-S
levels among fatal CHD cases (10), but several
smaller prospective case–control studies of fatal
and/or nonfatal CHD events (13–15) found no associ-
ation with DHEA-S levels. In larger prospective cohort
studies, we and others previously found an increased
risk of both all-cause and CVD mortality among
elderly men with the lowest DHEA/-S levels (16–18),
but other large studies found no association between
DHEA-S and CVD mortality in men (19,20). In addi-
tion, a population-based study reported no associa-
tion between DHEA-S levels and incident CVD in
2,084 middle-aged men (mean age 55 years) (35). The
Massachusetts Male Aging Study found no signiﬁcant
association between low DHEA/-S levels and 9-year
CHD mortality in 1,167 men age 40 to 70 years.
However, this study did ﬁnd an association betweenlow DHEA/-S levels and combined fatal and nonfatal
CHD events (151 events), but only when self-report of
treated CHD and CHD medication were included as
events in the analysis (23). Taken together, previous
data are conﬂicting, and there is a paucity of large
prospective analyses on this topic. Our study repre-
sents the largest study to date (302 men with CHD
events and 225 men with CBD events in 2,416 men at
risk), and strongly supports an association between
DHEA/-S levels and CHD risk in (elderly) men.
Experimental in vitro and rodent studies suggest
that DHEA/-S may modulate lipid and/or glucose me-
tabolism, systemic inﬂammation, vascular endothelial
function, and vascular remodeling via different me-
chanisms, such as peroxisome proliferator-activated
receptor-alpha activation, activation of a G-protein–
coupled receptor, or conversion to downstream DHEA
metabolites (1–3,9). However, because adult rodents
do not produce DHEA/-S in measurable amounts
due to lack of adrenal expression of the enzyme
CYP17 (36), results from rodent studies must be
interpreted with caution. Short-term trials on the
effect of DHEA therapy on vascular endothelial
function in humans have reported both improvement
(37,38) and no effect (39,40). Similarly, 4 longer
(6 months to 2 years) trials of DHEA therapy in
elderly persons showed conﬂicting results on the
effects on body composition and insulin action
(41–45). Notably, the association between DHEA/-S
and CHD risk in the present study was unaffected
by adjustment for traditional vascular risk factors.
Moreover, our results do not support systemic
inﬂammation as a mediator, because adjustment for
hsCRP level had no impact. Furthermore, we found
that the association between DHEA/-S and CHD risk
was not materially changed after adjustment for
serum testosterone and estradiol levels. Importantly,
this does not exclude a pivotal role for androgens or
estrogens produced locally by DHEA metabolism (4).
The ﬁndings of the present study should encourage
further mechanistic studies, preferably performed in
humans or other primates. These studies should
particularly address the possible direct actions of
DHEA on the vascular wall, for example, on endo-
thelial function and/or regeneration (2,36,46,47) and
the proliferation of vascular smooth muscle cells
(3,48,49).
Although collinear, the covariates of DHEA and
DHEA-S differed slightly. In line with previous ﬁnd-
ings that DHEA secretion follows a diurnal rhythm
similar to that of cortisol (2,16), DHEA was associated
with the time of blood sampling, whereas DHEA-S did
not show such an association, as expected from its
signiﬁcantly longer half-life (2). Importantly, DHEA,
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FIGURE 2 Unadjusted Kaplan-Meier Curves of Event-Free Survival by Serum DHEA Tertile for CHD and CBD Events
(A) Total number of participants with CHD events ¼ 302; (B) total number of participants with CBD events ¼ 225. The slate line is low
(tertile 1), the red line is intermediate (tertile 2), and the salmon line is high (tertile 3) serum DHEA concentration. The p values for trend over
tertiles assessed by log-rank test was p ¼ 0.015 for CHD and p ¼ 0.059 for CBD events, respectively. CBD ¼ cerebrovascular disease; other
abbreviations as in Figure 1.
TABLE 5 Hazard Ratios of DHEA for CHD Events: Exclusion of Subgroups
Number of CHD Events/
Number of Subjects HR (95% CI)
Per SD increase; Model 1
(from Table 4)
302/2,416 0.82 (0.73–0.93)
p ¼ 0.001
Per SD increase; Model 1
Exclusion of men with a
follow-up time of 2.6 yrs*
or less (n ¼ 215)
162/2,201 0.80 (0.68–0.94)
p ¼ 0.007
Per SD increase; Model 1
Exclusion of men with reduced renal
function (eGFR #45 mL/min/1.73 m2;
n ¼ 241)
260/2,175 0.86 (0.75–0.97)
p ¼ 0.019
Per SD increase; Model 1
Exclusion of men with non-morning
samples (n ¼ 750)
208/1,666 0.84 (0.73–0.96)
p ¼ 0.014
Per SD increase; Model 1
Exclusion of men with a baseline
history of myocardial infarction
(n ¼ 344)
211/2,072 0.85 (0.74–0.97)
p ¼ 0.019
Model 1: adjustment for age, MrOS site, morning sample. Log10-transformed values of DHEA were used. *Half of
the median follow-up time.
Abbreviations as in Tables 1 and 4.
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the multivariable models. It is conceivable that a “low
DHEA status” is not properly reﬂected by DHEA-S
levels, especially when renal function is reduced,
because of reduced renal clearance of the conjugated
(sulfated), and therefore, water soluble form of the
hormone. Thus, the impact of any systemic disease
on DHEA-S levels may be counteracted by concomi-
tant renal dysfunction (50). Nevertheless, adjustment
for renal function had no major impact on the asso-
ciation between DHEA or DHEA-S and CHD risk in our
study.
In the present study, both DHEA and DHEA-S blood
levels predicted CHD events. The relative biological
importance and pathways of DHEA and DHEA-S are
unclear, and the collinearity between DHEA and
DHEA-S precludes ﬁrm conclusions from statistical
analyses. The concentration of circulating DHEA is
approximately 350 times lower than that of DHEA-S,
but because it is more readily converted to down-
stream tissue metabolites, DHEA may be equally
important (1,2). Other data suggest that DHEA-S is
back-converted to DHEA only to a minor degree (2,51).
DHEA sulfation and desulfation are actively catalyzed
by sulfotransferase and sulfatase, respectively, which
may be regulated by different intraindividual and/orenvironmental factors and disease states (52,53).
Gaining further insight into the biological role of the
conjugated versus nonconjugated form of DHEA and
how DHEA sulfation is regulated are important tasks
for future studies.
CENTRAL ILLUSTRATION Possible Mechanisms for Adrenal-Derived DHEA/-S to Reduce Risk of CHD Events
This study demonstrates that lower circulating DHEA/S is associated with higher risk of CHD events. Possible protective mechanisms (salmon box) for DHEA/S on CHD
risk may either be mediated via the direct effects of DHEA/-S on target tissues or indirectly via local conversion to testosterone and/or estradiol in target tissues.
CHD ¼ coronary heart disease; DHEA ¼ dehydroepiandrosterone.
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health may lower DHEA/-S (22), comorbidity might
explain associations between DHEA/-S and CHD
events. Those who have poor general health (of any
cause) at baseline are more likely to die and/or
experience a CHD or non-CHD event soon after
baseline. Therefore, our ﬁnding that the association
between DHEA and CHD risk was unchanged
following exclusion of the ﬁrst 2.6 years of follow-up
argues against comorbidities confounding the
observed association.
The results of several small DHEA supplementation
studies are inconclusive (1). Although available data
does not support DHEA supplementation to elderly
people, there is widespread, nonsupervised use of
DHEA as a dietary supplement. Our results highlight
the need for further and larger trials of the car-
diometabolic consequences of DHEA therapy in
elderly subjects and/or subjects with low DHEA/-S
levels.
If DHEA/-S is cardioprotective, drugs that target its
synthesis may adversely affect CHD risk. Abiraterone
acetate, which inhibits the enzyme CYP17, which then
leads to inhibition of both DHEA and testosterone
biosynthesis, is a new therapy for advanced prostate
cancer. Abiraterone acetate was recently shown to
increase short-term overall survival in patients with
metastatic prostate cancer (54), but concerns about
potential cardiovascular side effects may be raised
due to its pronounced DHEA-lowering effect.
STUDY LIMITATIONS. The results were based on
single measurements of DHEA and DHEA-S, whichmight underestimate true associations. Because of
the diurnal variation in serum DHEA levels (16), the
use of some non-morning samples might have
contributed to increased variability, but the hour of
day was adjusted for in the analyses, and excluding
the participants without morning samples did not
materially change the results. Another limitation
was that baseline covariates were partly self-
reported, which is a potential source of residual
confounding. Older adults are often also treated
with more CVD medications, some of which could
alter cardiovascular risk and/or DHEA/-S levels.
Our study also had notable strengths, including
the mass spectrometry DHEA/-S methodology, a
large well-characterized sample, complete follow-
up, fatal and nonfatal outcomes, and the docu-
mented accuracy of classiﬁcation in nationwide
Swedish registers (30).
CONCLUSIONS
Low-serum levels of DHEA and its sulfate predicted
the risk of CHD, but not the risk of CBD, events in
elderly men.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
sulfated form of DHEA is the most abundant steroid
hormone in human blood. The exact physiological role of
DHEA/-S has not been deﬁned, but DHEA/-S levels are
lower in the elderly, in patients with Addison’s disease,
and in those with certain other conditions.
COMPETENCY IN PATIENT CARE: The safety and
efﬁcacy of routine DHEA supplementation have not been
established.
TRANSLATIONAL OUTLOOK: Properly designed
clinical trials are needed to evaluate the cardiometabolic
effects, safety, and efﬁcacy of DHEA supplementation
in clearly deﬁned study cohorts.
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